Uncategorized – Page 278

Regeneron Antitrust Suit Against Novartis Gains Momentum with Appellate Ruling

1 year ago talkbio0Tagged Antitrust, Appeal court backing, Eye treatments, Eylea & Lucentis, Legal patent, Novartis, Regeneron

Regeneron, Novartis, Antitrust lawsuit, Appeal court backing, Eye treatments (Eylea & Lucentis), Patent dispute

Bayer Prepares Menopause Drug Rival to Astellas’ Veozah for Regulatory Filings Following Successful Phase 3 Trials

1 year ago talkbio0Tagged Astellas, Bayer, competition, Elinzanetant, Menopause, regulatory approval, Veozah

Bayer, Menopause Drug, Elinzanetant, Phase 3 Hat Trick, Regulatory Approval, Competition with Astellas’ Veozah

Engrail Therapeutics Secures $157 Million in Mid-Stage Neuroscience Research Funding

1 year ago talkbio0Tagged Engrail, Funding, Generalized anxiety treatment, mid-stage neuroscience startup, Mood Disorders, Series B financing

Engrail Therapeutics, Mid-stage neuroscience startup, $157 million funding, Generalized anxiety treatment, Mood disorders, Series B financing

Bayer’s Menopause Drug Elinzanetant Achieves Successful Long-Term Results in Phase III Trial, Rivalling Astellas’ Veozah

1 year ago talkbio0Tagged Astellas, Bayer, competition, Elinzanetant, Hot flushes, Long-term, Menopause, Phase 3 Clinical Trials, vasomotor symptom, Veozah

Bayer, Elinzanetant, Menopause drug, Phase III trial, Long-term results, Hot flashes, Vasomotor symptoms, Astellas, Veozah, Competition

FDA Grants First Approval for Orchard Therapeutics’ Gene Therapy Lenmeldy in Treating Rare Pediatric Neuron Disease

1 year ago talkbio0Tagged Approved, Autologous Gene Therapy, Infantile/, Juvenile, Lenmeldy, Leukodystrophy, Metachromatic, Orchard, Pre-Symptomatic Late, Rare Pediatric Disease, United States Food and Drug Administration

Orchard Therapeutics, Lenmeldy, FDA Approval, Metachromatic Leukodystrophy (MLD), Rare Pediatric Disease, Autologous Gene Therapy, Pre-Symptomatic Late Infantile/ Early Juvenile Patients

“Continuum Biologics’ PIPE-791 Advances with Johnson & Johnson Partnership in Initial Public Offering (IPO)”

1 year ago talkbio0Tagged Biological Factors, Continuum, Demyelinating Diseases, IPO, Johnson & Johnson, LPAR1 antagonist, LPAR1 gene, Multiple Sclerosis, Neuroinflammation, PIPE-791, Public Offering, Receptors, Lysophosphatidic Acid

Continuum Biologics, PIPE-791, Johnson & Johnson partnership, Initial Public Offering (IPO), Multiple sclerosis, Demyelinating diseases, Neuroinflammation, LPAR1 antagonist, Lysophosphatidic acid receptor Edg-2 antagonist

AstraZeneca Joins Price Cap Movement for Inhalers Following Boehringer Investigation

1 year ago talkbio0Tagged AstraZeneca, Evaluation, Inhaler, Prices, SmithKline Beecham

Evaluation, Inhaler, AstraZeneca, SmithKline Beecham, Prices

AstraZeneca and GSK Join Boehringer Ingelheim in Capping Out-of-Pocket Inhaler Costs at $35 per Month

1 year ago talkbio0Tagged accessibility, AstraZeneca, GlaxoSmithKline/ Boehringer, Ingelheim, out-of-pocket costs/ cap/, Prices, U.S./ congressional

AstraZeneca/ GlaxoSmithKline/ Boehringer Ingelheim/ inhaler/ out-of-pocket costs/ cap/ $35/ asthma/ COPD/ price reduction/ drug pricing/ U.S./ congressional scrutiny/ patient affordability/ medication accessibility.